egfl7 protein Search Results


92
Sino Biological 11979 h07b
11979 H07b, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/11979 h07b/product/Sino Biological
Average 92 stars, based on 1 article reviews
11979 h07b - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

90
Novus Biologicals anti egfl7 antibody
Anti Egfl7 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti egfl7 antibody/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
anti egfl7 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
Proteintech antibody against egfl7
URRCC enhances <t>EGFL7</t> level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control
Antibody Against Egfl7, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against egfl7/product/Proteintech
Average 93 stars, based on 1 article reviews
antibody against egfl7 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Boster Bio pdgf elisa kits
Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of <t>PDGF</t> concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.
Pdgf Elisa Kits, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdgf elisa kits/product/Boster Bio
Average 90 stars, based on 1 article reviews
pdgf elisa kits - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
OriGene recombinant human egfl7
Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of <t>PDGF</t> concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.
Recombinant Human Egfl7, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human egfl7/product/OriGene
Average 90 stars, based on 1 article reviews
recombinant human egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Cusabio human egfl7 kits
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Human Egfl7 Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egfl7 kits/product/Cusabio
Average 92 stars, based on 1 article reviews
human egfl7 kits - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

90
Boster Bio egfl7
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Egfl7, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfl7/product/Boster Bio
Average 90 stars, based on 1 article reviews
egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Sino Biological recombinant mouse egfl7
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Recombinant Mouse Egfl7, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse egfl7/product/Sino Biological
Average 92 stars, based on 1 article reviews
recombinant mouse egfl7 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

94
Proteintech notch4 antibody
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Notch4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/notch4 antibody/product/Proteintech
Average 94 stars, based on 1 article reviews
notch4 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

90
Bioscientifica Ltd egfl7 protein
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Egfl7 Protein, supplied by Bioscientifica Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfl7 protein/product/Bioscientifica Ltd
Average 90 stars, based on 1 article reviews
egfl7 protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
PeproTech egf-l7
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Egf L7, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egf-l7/product/PeproTech
Average 90 stars, based on 1 article reviews
egf-l7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
ImmunoGen Inc monoclonal anti-human egfl7 antibodies
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Monoclonal Anti Human Egfl7 Antibodies, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal anti-human egfl7 antibodies/product/ImmunoGen Inc
Average 90 stars, based on 1 article reviews
monoclonal anti-human egfl7 antibodies - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


URRCC enhances EGFL7 level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: URRCC enhances EGFL7 level by mediating histone H3 acetylation of EGFL7 promoter. a : URRCC subnetwork according to the result of Target mRNA PCR Array. Genes colored in blue are down-regulated genes after that cells were transfected with sh-URRCC. Genes colored in red are up-regulated genes after that cells were transfected with sh-URRCC. The size of the gene round represents the fold change. b : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with sh-control or sh-URRCC. c : The mRNA and protein levels of EGFL7 were detected by qRT-PCR and WB assays in A498 and OSRC-2 cells after transfection with mock or oe-URRCC. d : EGFL7 expression in ccRCC and normal samples from TCGA KIRC dataset. e : Representative EGFL7 IHC staining of ccRCC tissues compared to paired normal renal tissues (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). f and g : Representative EGFL7 IHC staining of xenograft tumors from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×). Black scale bar represents 100 μm (200×) or 50 μm (400×). h : qRT-PCR and WB analysis of EGFL7 in A498 and OSRC-2 cells treated with DMSO or trichostatin A (TSA) (50 nM or 100 nM) for 72 h ( n = 3). i : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. j : ChIP analyses of A498 cells transfected with sh-control or sh-URRCC were conducted on the GAPDH promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. k : ChIP analyses of OSRC-2 cells transfected with mock or oe-URRCC were conducted on the EGFL7 promoter regions using anti-acetyl-histone H3 and anti-acetyl-histone H4. Enrichment was determined relative to input controls. The data are the means ± standard deviations of three independent biological replicates. l : EGFL7 promoter region was enriched with H3K27Ac histone mark presented with UCSC data. m : WB analysis of H3K27ac and total H3 in A498 and OSRC-2 cells treated with DMSO or TSA, β-actin was used as a loading control

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Transfection, Quantitative RT-PCR, Control, Expressing, Immunohistochemistry

URRCC is associated with EGFL7/P-AKT/FOXO3 signaling pathway. a and b : WB analysis of T-AKT, P-AKT, and FOXO3 in URRCC-overexpressing or URRCC-inhibited A498 and OSRC-2 cells compared with sh-control or mock group, β-actin was used as a loading control. c : CCK8 assays of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. d : Representative images and the numbers of invasive cells per high-power field reduced after the transfection with mock/oe-URRCC and si-NC/si-EGFL7 in A498 cells. e : WB analysis for EGFL7, T-AKT, P-AKT, and FOXO3 protein levels of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. β-actin was used as a loading control

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: URRCC is associated with EGFL7/P-AKT/FOXO3 signaling pathway. a and b : WB analysis of T-AKT, P-AKT, and FOXO3 in URRCC-overexpressing or URRCC-inhibited A498 and OSRC-2 cells compared with sh-control or mock group, β-actin was used as a loading control. c : CCK8 assays of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. d : Representative images and the numbers of invasive cells per high-power field reduced after the transfection with mock/oe-URRCC and si-NC/si-EGFL7 in A498 cells. e : WB analysis for EGFL7, T-AKT, P-AKT, and FOXO3 protein levels of A498 cells transfected with mock/oe-URRCC and si-NC/si-EGFL7. β-actin was used as a loading control

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Control, Transfection

A Schematic Diagram of LncRNA-URRCC-Based Signaling Pathway in ccRCC cells proliferation and invasion. LncRNA-URRCC upregulates AKT signaling by directly targeting EGFL7 via mediating histone H3 acetylation of EGFL7 promoter, and then inducing cell growth and invasion. AKT signaling downstream FOXO3 in turn downregulates URRCC by directly binding to its promoter

Journal: Molecular Cancer

Article Title: A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

doi: 10.1186/s12943-019-0998-y

Figure Lengend Snippet: A Schematic Diagram of LncRNA-URRCC-Based Signaling Pathway in ccRCC cells proliferation and invasion. LncRNA-URRCC upregulates AKT signaling by directly targeting EGFL7 via mediating histone H3 acetylation of EGFL7 promoter, and then inducing cell growth and invasion. AKT signaling downstream FOXO3 in turn downregulates URRCC by directly binding to its promoter

Article Snippet: Immunohistochemistry for the target molecules was performed on paraffin sections using a primary antibody against EGFL7 (1:50, proteintech, 19,291–1-AP), FOXO3 (1:500, Abcam, ab12162), P-AKT (1:50, Abcam, ab131443), Ki67 (1:500, Abcam, ab92742) and the proteins in situ were visualized with 3, 3-diaminobenzidine.

Techniques: Binding Assay

Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of PDGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.

Journal: Molecular medicine reports

Article Title: Characterization of bone marrow-derived mesenchymal stem cells from dimethyloxallyl glycine-preconditioned mice: Evaluation of the feasibility of dimethyloxallyl glycine as a mobilization agent.

doi: 10.3892/mmr.2016.4945

Figure Lengend Snippet: Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of PDGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.

Article Snippet: Mouse TGF (β IG-H3) and PDGF ELISA kits (Wuhan Boster Biological Co., Ltd., Wuhan, China) were used, according to the manufacturer's protocol.

Techniques: Concentration Assay, Expressing, Standard Deviation

EGFL7 levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.

Journal: Scientific Reports

Article Title: Circulating EGFL7 distinguishes between IUGR and PE: an observational case–control study

doi: 10.1038/s41598-021-97482-2

Figure Lengend Snippet: EGFL7 levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.

Article Snippet: Human EGFL7 kits were purchased from Cusabio Biotech (College Park, Maryland, USA).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Real-time Polymerase Chain Reaction, Gene Expression